Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Kojima, Takashi; A Shah, Manish; Muro, Kei; Francois, Eric; Adenis, Antoine; Hsu, Chih-Hung; Doi, Toshihiko; Moriwaki, Toshikazu; Kim, Sung-Bae; Lee, Se-Hoon; Bennouna, Jaafar; Kato, Ken; Shen, Lin; Enzinger, Peter; Qin, Shu-Kui; Ferreira, Paula; Chen, Jia; Girotto, Gustavo; de la Fouchardiere, Christelle; Senellart, Helene; Al-Rajabi, Raed; Lordick, Florian; Wang, Ruixue; Suryawanshi, Shailaja; Bhagia, Pooja; Peter Kang, S; Metges, Jean-Philippe; Investigators, KEYNOTE-181

doi:10.1200/JCO.20.01888

Public

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Shared by NobleBlocks on Dec 10, 2020 • 12:00 AM UTC

Authors:

Takashi Kojima

Manish A Shah

Kei Muro

Abstract

PURPOSE: Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS: In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamous cell carcinoma or adenocarcinoma o...

Discussions